Article

Micro-thin prescription inserts provide stable vision for patients with keratoconus

Paris—The 2-year follow-up of patients who received micro-thin prescription inserts (Intacs, Addition Technology) to treat keratoconus showed that the implants improved vision and maintained stable refractions, according to Joseph Colin, MD, from CHU Bordeaux, Bordeaux, France.

Eighty-two eyes were analyzed after implantation of the prescription inserts in this prospective study.

The results were very promising in that the cylinder decreased, the spherical equivalent decreased and then stabilized, and the best-corrected visual acuity (BCVA) and the uncorrected visual acuity levels (UCVA) increased in these eyes, according to Dr. Colin, who reported his results at the European Society of Cataract and Refractive Surgeons annual meeting.

"This procedure to treat keratoconus is safe and reversible and provides stable refractions," Dr. Colin said. "Between 1 and 2 years after the implantation of Intacs, the refractions remained stable."

"Two thirds of eyes had greater than a five-line increase in BCVA and UCVA; however, loss of lines of visual acuity is also a possibility," Dr. Colin concluded.

Related Videos
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Two-year data of bio-interventional cyclodialysis with scleral allograft with Leon W. Herndon Jr, MD
(Image credit: Ophthalmology Times) AGS 2025: Aqueous humor outflow improvement after excimer laser trabeculostomy with Clemens Strohmaier, PhD
(Image credit: Ophthalmology Times) Thomas W. Samuelson, MD, shares clinical perspectives on DSLT, SLT, and glaucoma management
Image credit: Ophthalmology Times; Dean McGee Eye Institute resident Ashley Ooms, MD, explores gray area strabismus surgery complications in AUPO poster
Image credit: Ophthalmology Times; EnVision Summit 2025: Sonia H. Yoo, MD, shares what to expect from the cataract and refractive agenda
Image credit: ©Ophthalmology Times
Wendy Lee, MD, talks about functional oculoplastics and aesthetics at EnVision Summit 2025
© 2025 MJH Life Sciences

All rights reserved.